<DOC>
	<DOCNO>NCT00799448</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare efficacy safety repaglinide combine insulin NPH versus biphasic human insulin 30 alone type 2 diabetic inadequately control sulfonylurea ( SU ) +/ biguanide therapy</brief_summary>
	<brief_title>Comparison Efficacy Safety Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone Inadequately Controlled Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<criteria>HbA1c : 7.511.0 % current therapy OHA ( oral hypoglycaemic agent ) treatment minimum two year BMI ( body mass index ) : 2532 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>